GT Biopharma (GTBP) Net Cash Flow (2010 - 2026)
GT Biopharma (GTBP) posted quarterly Net Cash Flow of $2.1 million for Q1 2026, up 233.17% year-over-year from $633919.8 in Q1 2025, and down 50.94% quarter-over-quarter from $4.3 million in Q4 2025.
GT Biopharma (GTBP) Net Cash Flow (2010 - 2026) Analysis & Trends
GT Biopharma (GTBP) has reported Net Cash Flow for 17 consecutive years, with $2.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 233.17% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $6.6 million (up 366.33% YoY), while the FY2025 annual figure was $2.9 million, down 3.04% from the prior year.
- Net Cash Flow fell to $2.1 million in Q1 2026 per GTBP's latest filing, from $4.3 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $4.3 million in Q2 2024 and bottomed at -$3.6 million in Q1 2023.
- Historically, Net Cash Flow has averaged -$158235.3 across 5 years, with a median of -$1.6 million in 2023.
- Annual changes were most pronounced in 2022 — Net Cash Flow surged 549.16% — and 2024, when it plunged 1611.25%.
- GT Biopharma's Net Cash Flow stood at $3.2 million in 2022, then sank by 148.92% to -$1.6 million in 2023, then slumped by 57.23% to -$2.5 million in 2024, then soared by 274.5% to $4.3 million in 2025, then tumbled by 50.94% to $2.1 million in 2026.
- Business Quant data shows GTBP's Net Cash Flow at $2.1 million in Q1 2026, $4.3 million in Q4 2025, and -$2.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | GT Biopharma | 8.64 Mn | 8.64 Mn | - | 2.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.11 Mn |
| Mar 31, 2026 | 2.11 Mn |
| Dec 31, 2025 | 4.31 Mn |
| Dec 31, 2025 | 4.31 Mn |
| Sep 30, 2025 | -2.71 Mn |
| Sep 30, 2025 | -2.71 Mn |
| Jun 30, 2025 | 2.86 Mn |
| Jun 30, 2025 | 2.86 Mn |
| Mar 31, 2025 | -1.59 Mn |
| Mar 31, 2025 | -1.59 Mn |
| Dec 31, 2024 | -2.47 Mn |
| Dec 31, 2024 | -2.47 Mn |
| Sep 30, 2024 | -2.74 Mn |
| Sep 30, 2024 | -2.74 Mn |
| Jun 30, 2024 | 4.32 Mn |
| Jun 30, 2024 | 4.32 Mn |
| Mar 31, 2024 | 871,000.00 |
| Mar 31, 2024 | 871,000.00 |
| Dec 31, 2023 | -1.57 Mn |
| Dec 31, 2023 | -1.57 Mn |